Table 3.
Ranking of incidence (A) and mortality (B) by expected percentages of the top 10 tumor types in males and females in 2020, 2025, and 2030
| (A)
|
(B)
|
||||||||
|---|---|---|---|---|---|---|---|---|---|
| Incidence
|
Mortality
|
||||||||
| Males | Females | Males | Females | ||||||
| 2020 | Colorectal | 16% | Breast | 19% | 2020 | Lung and bronchus | 29% | Lung and bronchus | 22% |
| Lung and bronchus | 16% | Colorectal | 12% | Colorectal | 17% | Colorectal | 14% | ||
| Prostate | 14% | Lung and bronchus | 11% | Prostate | 8% | Breast | 14% | ||
| Bladder | 7% | Corpus uteri | 4% | Pancreas | 6% | Pancreas | 7% | ||
| Oral cavity and pharynx | 6% | Pancreas | 4% | Oral cavity and pharynx | 6% | Ovary | 5% | ||
| Kidney | 4% | Ovary | 3% | Stomach | 5% | Stomach | 4% | ||
| Pancreas | 4% | Melanoma of skin | 3% | Bladder | 4% | Leukemia | 3% | ||
| Melanoma of skin | 3% | Bladder | 3% | Liver | 3% | Cervix uteri | 3% | ||
| Stomach | 3% | Cervix uteri | 3% | Leukemia | 3% | Gallbladder and biliary tract | 2% | ||
| Leukemia | 3% | Non-Hodgkin lymphoma | 3% | Kidney | 3% | Kidney | 2% | ||
| Other | 24% | Other | 35% | Other | 17% | Other | 24% | ||
| 2025 | Colorectal | 17% | Breast | 20% | 2025 | Lung and bronchus | 28% | Lung and bronchus | 23% |
| Prostate | 16% | Colorectal | 12% | Colorectal | 19% | Colorectal | 14% | ||
| Lung and bronchus | 14% | Lung and bronchus | 11% | Prostate | 9% | Breast | 14% | ||
| Bladder | 7% | Pancreas | 4% | Pancreas | 6% | Pancreas | 7% | ||
| Oral cavity and pharynx | 6% | Corpus uteri | 4% | Stomach | 5% | Ovary | 5% | ||
| Kidney | 4% | Melanoma of skin | 3% | Oral cavity and pharynx | 5% | Stomach | 4% | ||
| Pancreas | 4% | Ovary | 3% | Bladder | 5% | Leukemia | 3% | ||
| Melanoma of skin | 4% | Bladder | 3% | Liver | 3% | Cervix uteri | 3% | ||
| Stomach | 3% | Non-Hodgkin lymphoma | 3% | Leukemia | 3% | Kidney | 2% | ||
| Leukemia | 3% | Kidney | 3% | Kidney | 3% | Gallbladder and biliary tract | 2% | ||
| Other | 23% | Other | 34% | Other | 15% | Other | 23% | ||
| 2030 | Colorectal | 18% | Breast | 20% | 2030 | Lung and bronchus | 27% | Lung and bronchus | 23% |
| Prostate | 17% | Colorectal | 12% | Colorectal | 21% | Colorectal | 14% | ||
| Lung and bronchus | 13% | Lung and bronchus | 11% | Prostate | 10% | Breast | 13% | ||
| Bladder | 7% | Pancreas | 4% | Pancreas | 7% | Pancreas | 7% | ||
| Oral cavity and pharynx | 5% | Corpus uteri | 4% | Bladder | 5% | Ovary | 5% | ||
| Kidney | 4% | Melanoma of skin | 3% | Stomach | 5% | Stomach | 4% | ||
| Melanoma of skin | 4% | Ovary | 3% | Oral cavity and pharynx | 4% | Leukemia | 3% | ||
| Pancreas | 4% | Bladder | 3% | Liver | 4% | Cervix uteri | 3% | ||
| Leukemia | 3% | Non-Hodgkin lymphoma | 3% | Leukemia | 3% | Kidney | 2% | ||
| Stomach | 3% | Soft tissue | 3% | Kidney | 3% | Bladder | 2% | ||
| Other | 22% | Other | 34% | Other | 12% | Other | 24% | ||
Note: Incidence and mortality are expressed as mean values for each year.